Vertex Pharmaceuticals Rating Increased to Buy at Needham & Company (VRTX)

By admin | 6 years ago

Vertex Pharmaceuticals (NASDAQ: VRTX) was upgraded by investment analysts at Needham & Company from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The firm currently has a $65.00 target price on the stock.

Vertex Pharmaceuticals traded down 5.61% on Tuesday, hitting $60.56. Vertex Pharmaceuticals has a 1-year low of $26.50 and a 1-year high of $64.50. The company has a market cap of $12.770 billion and a price-to-earnings ratio of 45.63.

Vertex Pharmaceuticals last released its earnings data on Thursday, April 26th. The company reported $0.43 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.57 by $0.14. The company’s quarterly revenue was up 496.5% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $0.70 EPS next quarter.

Other equities research analysts have also recently issued reports about the stock. Analysts at Brean Murray Carret & Co. upgraded shares of Vertex Pharmaceuticals to a “buy” rating in a research note to investors on Monday. Separately, analysts at Brean Murray upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Monday. Finally, analysts at JPMorgan Chase (NYSE: JPM) reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note to investors on Monday.

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

About the author